International Prostate Forum

After participation in this CME activity, participants should be able to:
• Compare international prostate cancer screening guidelines and evaluate gaps between guideline recommendations and real-world clinical practice.
• Integrate emerging evidence from registry data and randomized trials to optimize prostate cancer screening and early detection strategies.
• Optimize the use of serum, urine, and imaging-based biomarkers to guide biopsy decisions and reduce overdiagnosis.
• Analyze evidence comparing prostate biopsy techniques, including systematic versus targeted sampling and fusion versus cognitive approaches.
• Apply risk-adapted strategies to active surveillance, including appropriate use of MRI, biopsy intensity, and adjunctive testing.
• Evaluate treatment selection for localized prostate cancer, including surveillance, focal therapy, radiation, and surgery, with emphasis on Grade Group 2 disease.
• Assess outcomes and complications associated with contemporary localized treatment approaches and implement strategies to improve patient outcomes.
• Determine evidence-based management strategies for node-positive and biochemically recurrent prostate cancer, incorporating advanced imaging and multimodal therapy.
• Implement treatment intensification strategies for metastatic hormone-sensitive prostate cancer, including appropriate selection of doublet versus triplet therapy.
• Select and sequence therapies for metastatic castration-resistant prostate cancer, including management of toxicities and the evolving role of radioligand therapy